Intervention of CAR-T Against Cervical Cancer

Cervical Cancer Clinical Trial

Official title:

Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Cervical Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03356795
• Other study ID #: GIMI-IRB-17017
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 15, 2017
• Est. completion date: December 2020

Study information

• Verified date: September 2019
• Source: Shenzhen Geno-Immune Medical Institute
• Contact: Lung-Ji Chang, PhD
• Phone: 86-075586725195
• Email: c[@]szgimi.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

Description:

Cervical cancer is a cancer arising from the cervix. Human papillomavirus (HPV) infection causes more than 90% of cases. Other risk factors include smoking, a weak immune system, birth control pills, starting sex at a young age, and having many sexual partners, but these are less important. Worldwide, cervical cancer is both the fourth-most common cause of cancer and the fourth-most common cause of death from cancer in women. The treatment of cervical cancer consists of surgical intervention, radiation, chemotherapy and immunotherapy.

In this study, the participant's T-cells will be collected and modified. Then the modified T cells, called chimeric antigen receptor modified-T cells (CAR T) which can recognize specific molecules that are expressed on the surface of cervical cancer cells, are given back to the participant by intravenous infusion.

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 2020
• Est. primary completion date: January 31, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Patients with stage III, IV or relapsed cervical cancer confirmed by histology and biopsy.

2. Age: = 18 years and = 70 years.

3. 4 weeks at least since last chemotherapy or radiotherapy and 2 weeks at least since last systemic steroid hormone and other immunosuppressive therapy.

4. Side Effects of Chemotherapy have subsided.

5. GD2, PSMA, Muc1, Mesothelin or other markers is expressed high (above 2+) in malignancy tissues by immuno-histochemical or flow cytometry.

6. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.

7. Expected survival = 12 weeks.

8. Initial hematopoietic reconstitution with

• neutrophils (ANC) = 1×10^6/L;

• platelet (PLT) = 1×10^8/L.

9. Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with

• serum creatinine = 2×ULN;

• serum bilirubin = 3×ULN;

• AST/ALT = 2.5×ULN.

10. Oxygen saturation = 90%.

11. Written, informed consent obtained prior to any study-specific procedures.

Exclusion Criteria:

1. Airway obstruction caused by tumor.

2. History of epilepsy or other central nervous system diseases.

3. Patients who require systemic corticosteroid or other immunosuppressive therapy.

4. History of prolonged or serious heart disease during QT.

5. history of serious cyclophosphamide toxicity.

6. Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study.

7. Inadequate liver and renal function with

• serum creatinine > 1.5 mg/dl;

• serum (total) bilirubin > 2.0 mg/dl;

• AST & ALT > 3 x ULN.

8. Pregnant or lactating females.

9. Serious active infection during screening.

10. Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection.

11. Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Biological:
• Cervical cancer-specific CAR-T cells
1 infusion, for 1x10^6~1x10^7 cells/kg via IV

Locations

Country	Name	City	State
China	Shenzhen Geno-immune Medical Institute	Shenzhen	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Shenzhen Geno-Immune Medical Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of CART cells in patients using CTCAE version 4.0 standard to evaluate the level of adverse events	Physiological parameter (measuring cytokine response)	3 months
Secondary	Persistence and proliferation of CART cells in patients	The expansion and functional persistence of CART cells in the peripheral blood of patients will be measured by qPCR on Day 7, 14, 21, 28, 60 and 90 after infusion.	3 months
Secondary	Anti-tumor effects	Objective response, such as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.	1 year